¶ dysbiosis
¶ Definition
Dysbiosis refers to an imbalance in the composition, diversity, or metabolic function of the microbiome, particularly in the gut, characterized by loss of beneficial commensal bacteria, overgrowth of pathobionts (opportunistic pathogens), and reduced microbial diversity (typically <100 species vs. 500-1000 in healthy individuals). This state disrupts the host-microbe symbiosis that evolved over millions of years, driving chronic low-grade inflammation, metabolic dysfunction, and contributing to numerous disease states through impaired barrier function, altered immune signaling, and loss of beneficial microbial metabolites.
¶ Picture It
Imagine your gut microbiome as a well-tended garden ecosystem. In a healthy garden, you have diverse plant species—deep-rooted trees (keystone commensal bacteria like Akkermansia-muciniphila), nitrogen-fixing plants (SCFA producers), and ground cover that keeps weeds at bay. The gardeners (immune cells) maintain peaceful coexistence with these plants, receiving oxygen, shade, and food in return.
Now picture this garden after weeks of pesticide spraying (antibiotics), fertilizer overload (processed foods, sugar), and drought (stress, poor sleep). The deep-rooted trees die first—they're sensitive and slow-growing. Aggressive weeds (proteobacteria like Escherichia coli, Enterobacter) explode in their place because they thrive in disturbed soil. The ground cover vanishes, exposing bare patches (reduced diversity). Without nitrogen-fixing plants, the soil becomes depleted (Butyrate drops from 20-25% of colonic energy to <10%).
The weeds produce toxic chemicals (LPS, TMAO) that leak through the now-cracked fence (increased intestinal permeability) into neighboring properties (bloodstream). The gardeners, instead of maintaining order, become hypervigilant firefighters (chronic low-grade inflammation), constantly responding to alarm signals but never resolving the root problem. The entire neighborhood ecosystem—including distant properties like the brain (gut-brain axis) and joints—suffers from the upstream chaos.
¶ Mechanism
Dysbiosis disrupts host-microbe homeostasis through multiple interconnected pathways:
Loss of Beneficial Commensals:
- SCFA-producing bacteria (Faecalibacterium prausnitzii, Roseburia, Eubacterium) decline → reduced Butyrate production (from 15-25 mM in healthy colon to <5 mM)
- Butyrate normally activates GPR109A and GPR41 receptors on colonocytes → FOXO pathway activation → increased tight junctions expression (occludin, ZO-1)
- Loss of butyrate → impaired colonocyte energy (butyrate provides 70% of colonocyte ATP) → barrier breakdown
- Butyrate also inhibits HDACs → promotes Treg differentiation via enhanced FOXP2 mutation expression and IL-10 production
- Reduced Akkermansia-muciniphila (normally 1-4% of microbiota) → decreased mucin degradation → thinner mucus layer (from 200-800 μm to <100 μm) → bacteria closer to epithelium
Pathobiont Overgrowth:
- Proteobacteria expansion (Escherichia, Klebsiella, Enterobacter) → increased gram-negative bacteria → elevated LPS (lipid-A moiety) in gut lumen
- LPS binds LBP (LPS-binding protein) → transfers to CD14 → TLR4 activation on enterocytes and immune cells
- TLR4 activation → MyD88 → NF-κB translocation → transcription of IL-1β, IL-6, TNF-α, IL-8
- Porphyromonas gingivalis (from oral cavity in periodontal disease) translocates to gut → produces Siderophores (bacterial iron-chelating molecules)
- Siderophores sequester iron → iron dysregulation → reduced iron availability for host → anemia of chronic disease
- Sequestered iron also fuels oxidative stress: Fe²⁺ + H₂O₂ → Fe³⁺ + OH• (hydroxyl radical) via Fenton reaction
Barrier Dysfunction and Translocation:
- Pathobiont proteases and toxins (e.g., α-hemolysin, zonulin-inducing factors) → tight junctions disassembly
- Increased intestinal permeability (normally <2% lactulose/mannitol ratio, rises to >5% in dysbiosis)
- bacterial translocation → LPS and bacterial components enter portal circulation → liver exposure
- Hepatic Kupffer cells (resident macrophages) detect LPS → TNF-α and IL-6 release → acute phase response
- Systemic Endotoxaemia (LPS >50 pg/mL vs. <10 pg/mL in health) → widespread low-grade inflammation
Metabolic Dysregulation:
- Altered bile acid metabolism: reduced bacterial bile salt hydrolases → decreased secondary bile acids (deoxycholate, lithocholate)
- Secondary bile acids normally activate FXR and TGR5 receptors → metabolic regulation and GLP-1 secretion
- Loss of this signaling → impaired glucose metabolism, reduced insulin sensitivity
- Increased trimethylamine (TMA) production from dietary choline/carnitine → hepatic conversion to TMAO via FMO3
- TMAO >6 μM → promotes atherosclerosis, platelet hyperreactivity, vascular inflammation
- Reduced SCFA production → decreased GLP-1 and PYY secretion from enteroendocrine L cells → impaired satiety, glucose homeostasis
Immune Dysregulation:
- Loss of commensal-derived signals (e.g., polysaccharide A from Bacteroides fragilis) → reduced Treg induction
- Treg populations decline from 10-15% of CD4+ T cells to <5% in severe dysbiosis
- Loss of tolerogenic dendritic cell conditioning → increased Th1/Th17 responses
- Molecular mimicry: bacterial antigens share epitopes with host proteins → cross-reactive antibodies → autoimmune disease
- Example: Klebsiella antigens mimic HLA-B27 → triggers ankylosing spondylitis in susceptible individuals
graph TD
A[Dysbiosis Triggers] --> B[Antibiotic Use]
A --> C[High Sugar/Low Fiber Diet]
A --> D[Chronic Stress]
A --> E[NSAIDs/PPIs]
B --> F[Loss of Commensal Diversity]
C --> F
D --> F
E --> F
F --> G[Reduced SCFA Production]
F --> H[Pathobiont Overgrowth]
G --> I[Impaired Colonocyte Energy]
G --> J[Reduced Treg Differentiation]
I --> K[Barrier Breakdown]
H --> L[Increased LPS Production]
H --> M[Siderophore Release]
L --> N[TLR4 Activation]
N --> O["NF-κB → Pro-inflammatory Cytokines"]
K --> P[Bacterial Translocation]
P --> Q[Endotoxemia]
Q --> O
M --> R[Iron Sequestration]
R --> S[Oxidative Stress]
R --> T[Anemia]
O --> U[Chronic Low-Grade Inflammation]
J --> V[Loss of Immune Tolerance]
V --> W[Autoimmunity Risk]
U --> X[Metabolic Dysfunction]
U --> Y[Neuroinflammation]
U --> Z[Multi-organ Disease]
¶ Clinical Significance
Dysbiosis represents a central mechanistic hub in clinical PNI, linking evolutionary mismatch (modern diet, antibiotics, sanitized environments) to the pandemic of chronic inflammatory diseases. This is Metamodel 1 in action: the microbiome as evolutionary partner suddenly becomes pathogenic when environmental inputs violate ancestral expectations.
Relevant Patient Populations:
- GI disorders: irritable bowel syndrome (IBS) shows reduced Faecalibacterium prausnitzii and increased Ruminococcus gnavus; inflammatory bowel disease (IBD, both Crohn's and ulcerative colitis) shows 30-50% reduction in microbial diversity with proteobacteria dominance
- Metabolic syndrome: dysbiosis precedes obesity and type 2 diabetes—Akkermansia-muciniphila depletion correlates with insulin resistance (HOMA-IR >2.5)
- Autoimmune conditions: rheumatoid arthritis patients show Prevotella copri expansion; type 1 diabetes shows reduced Bifidobacterium in early life
- Neuropsychiatric: depression correlates with reduced butyrate producers; autism shows distinct dysbiotic signature with elevated Clostridium species
- Cardiovascular: elevated TMAO (>6.2 μM) predicts 2.5× increased cardiovascular event risk
Connection to cPNI Frameworks:
- Selfish Immune System: dysbiosis forces the immune system into permanent defensive mode, prioritizing inflammation over tissue repair/tolerance—classic allostatic load
- 5+2 Metamodel: dysbiosis appears in both "biological amplification" (small inflammatory triggers become chronic) and "evolutionary mismatch" (microbiome expecting fiber, getting sugar)
- Associated Molecular Patterns (AMPs): dysbiosis creates specific inflammatory signatures—elevated IL-6, CRP, fecal calprotectin (>50 μg/g), serum LPS-binding protein
Assessment Tools:
- Stool microbiome analysis: diversity indices (Shannon index
.0 suggests dysbiosis), Firmicutes:Bacteroidetes ratio (>10:1 or <0.5:1 abnormal) - Functional markers: Butyrate measurement (HPLC), fecal SCFA profile
- Inflammatory markers: fecal calprotectin, serum LBP (LPS-binding protein), Endotoxaemia assays
- Permeability: lactulose/mannitol test (>0.03 suggests leaky gut)
- Metabolic: plasma TMAO, urine organic acids
Intervention Implications:
- Restore diversity: prebiotics (15-30g fiber/day targeting resistant starch, inulin), diverse polyphenol sources
- Repopulate: targeted probiotics (Lactobacillus rhamnosus GG, Bifidobacterium longum, Saccharomyces boulardii), fermented foods
- Remove triggers: eliminate unnecessary antibiotics, reduce processed foods, NSAIDs, PPIs
- Support barrier: zinc (30-50mg/day), L-glutamine (5-15g/day), vitamin D optimization (>75 nmol/L)
- Address oral source: treat periodontal disease to prevent Porphyromonas gingivalis translocation
- Stress axis: chronic stress management (cortisol disrupts microbiome via reduced sIgA, altered gut motility)
¶ Key Facts
- Healthy microbiome contains 500-1000 bacterial species; dysbiosis typically <100 species with reduced diversity (Shannon index .0)
- Butyrate-producing bacteria decline is hallmark finding—butyrate provides 70% of colonocyte energy and regulates 10-15% of colonic Treg cells
- Proteobacteria expansion (Enterobacteriaceae family) is inflammatory signature—correlates with CRP >3 mg/L and IL-6 >2 pg/mL
- Akkermansia-muciniphila normally comprises 1-4% of gut microbiota; depletion to <0.5% associates with metabolic dysfunction and obesity
- Systemic Endotoxaemia threshold: LPS >50 pg/mL drives metabolic inflammation; healthy baseline <10 pg/mL
- Oral dysbiosis (periodontal disease) contributes systemically—Porphyromonas gingivalis detected in 87% of atherosclerotic plaques
- Siderophores from dysbiotic bacteria sequester iron, creating functional iron deficiency despite normal ferritin—check transferrin saturation <20%
- Fecal calprotectin >50 μg/g indicates intestinal inflammation; >200 μg/g suggests IBD vs. IBS
- TMAO production from dysbiotic metabolism of choline/carnitine—levels >6.2 μM predict 2.5× cardiovascular risk
- Antibiotic use reduces microbiome diversity by 25-50% within days; full recovery may take 6-12 months or never occur completely
- Intestinal permeability rises 2-5× in dysbiosis (lactulose/mannitol ratio >0.03), allowing bacterial translocation and systemic inflammation
- Dysbiosis-associated chronic low-grade inflammation shows CRP 3-10 mg/L, IL-6 2-5 pg/mL—below acute infection but above healthy baseline
¶ Connections
- microbiome — dysbiosis is fundamental disruption of microbiome composition, diversity, and function
- gut microbiome — primary site of dysbiosis; loss of commensal diversity and pathobiont overgrowth
- oral microbiome — Oral dysbiosis (periodontal disease) seeds gut with pathogenic bacteria like Porphyromonas gingivalis
- SCFA — dysbiosis drastically reduces SCFA production, particularly Butyrate, disrupting colonocyte energy and Treg differentiation
- Butyrate — keystone metabolite lost in dysbiosis; normally 15-25 mM in colon, drops to <5 mM; activates GPR109A, GPR41, inhibits HDACs
- intestinal permeability — dysbiosis primary driver of leaky gut via loss of butyrate, pathobiont proteases, and inflammatory cytokines
- LPS — gram-negative pathobiont overgrowth massively increases LPS load, triggering TLR4 pathway and systemic inflammation
- Endotoxaemia — dysbiosis enables bacterial translocation and elevated systemic LPS (>50 pg/mL), driving metabolic inflammation
- chronic low-grade inflammation — dysbiosis is upstream driver; creates persistent inflammatory state via LPS, reduced SCFAs, barrier dysfunction
- Porphyromonas gingivalis — oral pathogen translocating to gut in dysbiosis; produces Siderophores, drives iron dysregulation and oxidative stress
- Siderophores — bacterial iron-chelating molecules increased in dysbiosis; sequester iron, fuel Fenton reaction oxidative damage
- iron — dysbiosis creates dual problem: bacterial Siderophores sequester iron while inflammation raises hepcidin, blocking absorption
- Akkermansia-muciniphila — beneficial commensal depleted in dysbiosis; normally 1-4%, drops to <0.5%; loss associates with metabolic dysfunction
- TMAO — dysbiotic bacteria overproduce trimethylamine from choline/carnitine → hepatic conversion to TMAO → cardiovascular risk
- bile acid — dysbiosis alters bile acid metabolism; reduced deconjugation and 7α-dehydroxylation → loss of FXR/TGR5 signaling
- Treg — dysbiosis reduces Treg differentiation via loss of butyrate and commensal signals; drops from 10-15% to <5% of CD4+ cells
- tight junctions — dysbiosis degrades tight junctions (occludin, ZO-1) via reduced butyrate, increased inflammatory cytokines, pathobiont toxins
- TLR4 — primary receptor detecting increased LPS from dysbiotic gram-negative bacteria; triggers NF-κB inflammatory cascade
- NF-κB — master inflammatory transcription factor activated by dysbiosis-derived LPS, DAMPs; drives IL-6, TNF-α, IL-1β expression
- antibiotics — major cause of dysbiosis; reduce diversity 25-50%, kill beneficial commensals preferentially, promote resistant pathobiont overgrowth
- diet — Western diet (high sugar, low fiber, processed foods) primary dysbiosis driver; starves SCFA producers, feeds pathobionts
- stress — chronic stress alters microbiome via elevated cortisol, reduced sIgA, altered motility, increased permeability
- inflammatory bowel disease — severe dysbiosis with 30-50% diversity loss, proteobacteria dominance, mucosal adherence; both cause and consequence
- irritable bowel syndrome — functional disorder with dysbiotic signature: reduced Faecalibacterium prausnitzii, increased Ruminococcus gnavus
- obesity — dysbiosis precedes weight gain; altered Firmicutes:Bacteroidetes ratio, reduced Akkermansia-muciniphila, increased energy harvest
- type 2 diabetes — dysbiosis-driven insulin resistance via Endotoxaemia, reduced GLP-1, elevated TMAO, chronic inflammation
- metabolic syndrome — dysbiosis core feature; drives insulin resistance, dyslipidemia, hypertension via inflammation and metabolic reprogramming
- autoimmune disease — dysbiosis triggers via Molecular Mimicry (bacterial antigens cross-react with self), loss of Treg tolerance, barrier breach
- Depression — dysbiosis reduces butyrate and tryptophan metabolism, increases kynurenine pathway, elevates systemic IL-6 → neuroinflammation
- gut-brain axis — dysbiosis disrupts bidirectional signaling; reduced SCFA, elevated LPS, altered neurotransmitter precursors affect brain function
- periodontal disease — oral dysbiosis source; Porphyromonas gingivalis translocates to gut, produces inflammatory mediators, drives systemic disease
- calprotectin — fecal marker of intestinal inflammation in dysbiosis; >50 μg/g abnormal, >200 μg/g suggests IBD
- oxidative stress — dysbiosis-driven via Siderophores-iron Fenton reaction, reduced antioxidant capacity, inflammatory ROS production
- inflammation — dysbiosis maintains chronic inflammatory state through multiple pathways: LPS, reduced SCFA, barrier dysfunction, immune dysregulation
¶ Module References
- Module 1